Cited by 0Genomics and Rare DiseasesPediatric Hepatobiliary Diseases and TreatmentsLiver Diseases and Immunity

Exome Sequencing Reanalysis Improves Molecular Diagnosis in Genetic Cholestatic Liver Diseases

Open access
Rodriguez, Maël Silva, Larbaoui, Adel, Largo, Mélissa, Goksen, Betul, Haghnejad, Vincent, Bensenane, Mouni, Chéry, Céline, Daude, Sébastien +6 more·2026·JHEP Reports

Abstract

BACKGROUND AND AIMS: The 2024 European Association for the Study of the Liver (EASL) guidelines recommend periodic reanalysis of exome data in genetic cholestatic liver diseases, although supporting evidence remains limited and optimal gene panel composition has not been established. We evaluated the molecular diagnostic yield of systematic reanalysis of clinical exome sequencing (CES) data and compared cholestasis-focused gene panels. METHODS: Consecutive patients referred for CES at a tertiary center for suspected genetic cholestatic liver disease (January 2021 to February 2025) were included. The initial analysis (A1) was compared with a reanalysis (A2) using three in silico panels: the Cholestasis Nancy Panel (41 genes), the EASL 2024 panel (18 genes), and an LPAC panel (8 genes). The primary endpoint was the difference in likely pathogenic or pathogenic (LP/P) yield between A1 and A2. The secondary endpoint added variants of uncertain significance (VUS). RESULTS: Among 86 patients (median age 35 years; 63% female; 83% adults), the LP/P yield increased from 30% (26/86) to 43% (37/86) (95% CI, 5-21; P=0.006). At reanalysis, the Cholestasis Nancy Panel provided an incremental diagnostic yield beyond the Cholestasis EASL 2024 core panel at both thresholds (43% vs 34%, P = 0.013; 69% vs 49%, P=0.0001). At the LP/P threshold, the incremental yield was significant for cholelithiasis/LPAC (P=0.004) but unchanged for unexplained cholestasis, Alagille syndrome, and BRIC/PFIC. At the VUS/LP/P threshold, the increase was also significant for unexplained cholestasis (P=0.003). SERPINA1 was the most frequently implicated gene. CONCLUSIONS: Systematic CES reanalysis increases molecular diagnostic yield in genetic cholestatic liver diseases, particularly in clinically challenging presentations. Performed within an accredited CES platform, periodic reappraisal of data as knowledge evolves warrants integration into routine practice. CLINICAL TRIAL NUMBER: Not applicable.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jhepr.2026.102076

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Still being checked.

Authors
Rodriguez, M. S., Larbaoui, A., Largo, M., Goksen, B., Haghnejad, V., Bensenane, M., Chéry, C., Daude, S., Bonneton, M., Lambert, L., Feillet, F., Namour, F., Bronowicki, J.-P., & Oussalah, A.
Affiliations
  • Inserm (FR)
  • Université de Lorraine (FR)
  • Centre Hospitalier Régional et Universitaire de Nancy (FR)
Corresponding author
Oussalah, Abderrahim
Venue
JHEP Reports
Publisher
Elsevier BV
Published
2026-10
Pages
102076
ISSN
2589-5559 (ISSN-L)
OpenAlex
W7223465826
Cited by
0
References
36
FWCI
0.00
Type
journal article
Language
en
Open access
Locations
  • JHEP Reports (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Universite de Lorraine
  • CHRU de Nancy
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
molecular diagnosis, variants of uncertain significance, SERPINA1, gallstones, Alagille syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review